

Patient Report



Specimen ID: 068-996-9612-0
Control ID:

Acct #: 90000999 Phone: (336) 436-8645 Rte: 00
LabCorp Test Master
Test Account
5450 Millstream Road
MCLEANSVILLE NC 27301

SAMPLE REPORT, 140303

Patient Details

DOB: 01/01/1975
Age(y/m/d): 047/02/08
Gender: F
Patient ID:

Specimen Details

Date collected: 03/09/2022 0000 Local
Date received: 03/09/2022
Date entered: 03/09/2022
Date reported: 03/11/2022 0000 ET

Physician Details

Ordering:
Referring:
ID:
NPI:

General Comments & Additional Information

Clinical Info: NORMAL REPORT

Total Urine Volume: 1400ml

Fasting: Not Provided

Ordered Items

Kidney Profile+CMP14; Litholink CKD Program

TESTS	RESULT	FLAG	UNITS	REFERENCE INTERVAL	LAB
Kidney Profile+CMP14					
Glucose	75		mg/dL	65-99	01
BUN	10		mg/dL	6-24	01
Creatinine	0.75		mg/dL	0.57-1.00	01
eGFR	99		mL/min/1.73	>59	01
Comment:					01
Current medical guidelines define chronic kidney disease (CKD) as an estimated glomerular filtration rate (eGFR) <60 mL/min/1.73 m ² and/or urine albumin/creatinine ratio >30 mg/g present for more than three months.					
BUN/Creatinine Ratio	13			9-23	
Sodium	135		mmol/L	134-144	01
Potassium	4.0		mmol/L	3.5-5.2	01
Chloride	100		mmol/L	96-106	01
Carbon Dioxide, Total	25		mmol/L	20-29	01
Calcium	9.0		mg/dL	8.7-10.2	01
Protein, Total	8.0		g/dL	6.0-8.5	01
Albumin	4.8		g/dL	3.8-4.8	01
Globulin, Total	3.2		g/dL	1.5-4.5	
A/G Ratio	1.5			1.2-2.2	
Bilirubin, Total	1.0		mg/dL	0.0-1.2	01
Alkaline Phosphatase	115		IU/L	44-121	01
AST (SGOT)	24		IU/L	0-40	01
ALT (SGPT)	10		IU/L	0-32	01
Creatinine, Urine	150.0		mg/dL	Not Estab.	01
Albumin, Urine	25.0		ug/mL	Not Estab.	01
Alb/Creat Ratio	17		mg/g creat	0-29	
Normal:				0 - 29	
Moderately increased:				30 - 300	
Severely increased:				>300	

Patient Report



Patient: **SAMPLE REPORT, 140303**
 DOB: 01/01/1975

Patient ID:

Control ID:

Specimen ID: 068-996-9612-0
 Date collected: 03/09/2022 0000 Local

TESTS	RESULT	FLAG	UNITS	REFERENCE INTERVAL	LAB
-------	--------	------	-------	--------------------	-----

Litholink CKD Program

Interpretation Note 02

Medical Director's Note: Effective 2/28/2022, Labcorp uses the 2021 CKD-EPI creatinine equation without a race factor to calculate and report eGFR results. eGFR results reported prior to this date using the 2009 CKD-EPI equation are no longer included in this report interpretation.

 CHRONIC KIDNEY DISEASE:
 EGFR, BLOOD PRESSURE, AND PROTEINURIA ASSESSMENT
 Estimated GFR is 60 mL/min/1.73mE2 or above; this patient is not presently in CKD stage 3 or higher, therefore we are unable to provide suggestions for treatment or follow-up.

 DISCLAIMER
 These assessments and treatment suggestions are provided as a convenience in support of the physician-patient relationship and are not intended to replace the physician's clinical judgment. They are derived from national guidelines in addition to other evidence and expert opinion. The clinician should consider this information within the context of clinical opinion and the individual patient. SEE GUIDANCE FOR CHRONIC KIDNEY DISEASE PROGRAM: Kidney Disease Improving Global Outcomes (KDIGO) clinical practice guidelines are at <http://kdigo.org/home/guidelines/>. National Kidney Foundation Kidney Disease Outcomes Quality Initiative (KDOQI (TM)), with its limitations and disclaimers, are at www.kidney.org/professionals/KDOQI. This program is intended for patients who have been diagnosed with stages 3, 4, or pre-dialysis 5 CKD. It is not intended for children, pregnant patients, or transplant patients.

PDF 02

01	RN	Labcorp Raritan 69 First Avenue, Raritan, NJ 08869-1800	Dir: Araceli B Reyes, MD
02	LITIL	Litholink Corporation 150 Spring Lake Dr Ste A, Itasca, IL 60143-2091	Dir: John Asplin, MD

For inquiries, the physician may contact **Branch: 800-222-7566 Lab: 800-631-5250**

Accessions: 06899696120

DISCLAIMER: These assessments and treatment suggestions are provided as a convenience in support of the physician-patient relationship and are not intended to replace the physician's clinical judgment. They are derived from national guidelines in addition to other evidence and expert opinion. The clinician should consider this information within the context of clinical opinion and the individual patient.

SEE GUIDANCE FOR CHRONIC KIDNEY DISEASE PROGRAM: Kidney Disease Improving Global Outcomes (KDIGO) clinical practice guidelines are at <http://kdigo.org/home/guidelines/>. National Kidney Foundation Kidney Disease Outcomes Quality Initiative (KDOQI (TM)), with its limitations and disclaimers, are at www.kidney.org/professionals/KDOQI. This program is intended for patients who have been diagnosed with stages 3, 4, or pre-dialysis 5 CKD. It is not intended for children, pregnant patients, or transplant patients.

Note: Please refer to your LabCorp Report for all results as well as any test-specific and specimen-specific comments.

Laboratory Director's Notes

Laboratory test values flagged with an asterisk (*) within this report refer to the following commentary from our physicians and quality assurance staff.

COLLECTION DATE	ITEM	RELATED NOTES
03/09/2022		Effective 2/28/2022, Labcorp uses the 2021 CKD-EPI creatinine equation without a race factor to calculate and report eGFR results. eGFR results reported prior to this date using the 2009 CKD-EPI equation are no longer included in this report interpretation.

John Asplin, MD - Laboratory Director

Chronic Kidney Disease

Analysis & Treatment Suggestions

GENDER	DIABETES	CURRENT eGFR	MOST RECENT CKD STAGE
F	?	99	

Prognosis of CKD by GFR And Albuminuria Categories

GFR Categories: (ml/min/1.73m ²)		A1	A2	A3
G1	>=90 NORMAL OR HIGH			
G2	60-89 MILDLY DECREASED			
G3a	45-59 MILDLY TO MODERATELY DECREASED			
G3b	30-44 MODERATELY TO SEVERELY DECREASED			
G4	15-29 SEVERELY DECREASED			
G5	<15 KIDNEY FAILURE			

Persistent Albuminuria Categories

A1 = NORMAL TO MILDLY INCREASED; ACR <30 ug/mg; PCR <=200 mg/g

A2 = MODERATELY INCREASED; ACR 30-300 ug/mg; PCR 201-500 mg/g

A3 = SEVERELY INCREASED; ACR >300 ug/mg; PCR >500 mg/g

= LOW RISK

= MODERATELY INCREASED RISK

= HIGH RISK

= VERY HIGH RISK

= PATIENT'S RESULT

Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. *Kidney inter.; Suppl.* 2013; 3: 1-150.

eGFR, Blood Pressure, and Proteinuria

Estimated GFR is 60 mL/min/1.73m² or above; this patient is not presently in CKD stage 3 or higher, therefore we are unable to provide suggestions for treatment or follow-up.

Your Test Results



WITHIN GOAL



BORDERLINE



OUT OF GOAL

Test	Your Results	Comments
------	--------------	----------



Kidney Health

eGFR estimates how well your kidneys are filtering blood. The higher the number, the better your kidneys are working.

99

Ref Range: >59
mL/min/1.73mE2

YOUR RESULT SHOWS NORMAL KIDNEY FUNCTION. Control of diabetes and blood pressure can help to preserve kidney function.

URINE ALBUMIN : CREATININE RATIO is a test that looks for albumin in the urine, a sign of kidney damage. Higher amounts also put you at risk for heart disease and loss of kidney function. The lower the result, the better.



16.7

Ref. Range: 0 to 30 mg/g creat

YOUR URINE ALBUMIN IS NORMAL. Controlling conditions like high blood pressure and diabetes can help keep your urine albumin in the normal range. Regular exercise, weight loss, and quitting smoking are also beneficial for both heart and kidney health.

DISCLAIMER: You should discuss this information with your physician. Labcorp does not have a doctor-patient relationship with you, nor does it have access to a complete medical history or physical examination conducted by a physician that would be necessary for a complete diagnosis and comprehensive treatment plan. Neither you nor your physician should rely solely on this guidance. Bolded result descriptions in "Comments" consider either the reference range or target range for the test result. Reference range refers to the Labcorp reference interval. Target range refers to the guideline-suggested goal. REFERENCES: National Kidney Foundation Kidney Disease Outcomes Quality Initiative (KDOQI) at www.Kidney.org and Kidney Disease Improving Global Outcomes (KDIGO) at <http://kdigo.org>. Adapted from: https://www.niddk.nih.gov/-/media/Files/Health-Information/Health-Professionals/Kidney-Disease/Your_Kidney_Test_Results_EN.pdf.



Patient Report



Specimen ID: 068-996-9613-0
Control ID:

Acct #: 90000999
LabCorp Test Master
Test Account
5450 Millstream Road
MCLEANSVILLE NC 27301

Phone: (336) 436-8645 Rte: 00

SAMPLE REPORT, 140303

Patient Details

DOB: 01/10/2000
Age(y/m/d): 022/01/27
Gender: F
Patient ID:

Specimen Details

Date collected: 03/09/2022 0000 Local
Date received: 03/09/2022
Date entered: 03/09/2022
Date reported: 03/11/2022 0000 ET

Physician Details

Ordering:
Referring:
ID:
NPI:

General Comments & Additional Information

Clinical Info: ABNORMAL REPORT

Total Urine Volume: 1200ml

Fasting: Not Provided

Ordered Items

Kidney Profile+CMP14; Litholink CKD Program

TESTS	RESULT	FLAG	UNITS	REFERENCE INTERVAL	LAB
Kidney Profile+CMP14					
Glucose	125	High	mg/dL	65-99	01
BUN	21	High	mg/dL	6-20	01
Creatinine	1.25	High	mg/dL	0.57-1.00	01
eGFR	62		mL/min/1.73	>59	
Comment:					01
Current medical guidelines define chronic kidney disease (CKD) as an estimated glomerular filtration rate (eGFR) <60 mL/min/1.73 m ² and/or urine albumin/creatinine ratio >30 mg/g present for more than three months.					
BUN/Creatinine Ratio	17			9-23	
Sodium	145	High	mmol/L	134-144	01
Potassium	4.0		mmol/L	3.5-5.2	01
Chloride	100		mmol/L	96-106	01
Carbon Dioxide, Total	25		mmol/L	20-29	01
Calcium	10.0		mg/dL	8.7-10.2	01
Protein, Total	8.4		g/dL	6.0-8.5	01
Albumin	5.1	High	g/dL	3.9-5.0	01
Globulin, Total	3.3		g/dL	1.5-4.5	
A/G Ratio	1.5			1.2-2.2	
Bilirubin, Total	1.0		mg/dL	0.0-1.2	01
Alkaline Phosphatase	120		IU/L	44-121	01
AST (SGOT)	41	High	IU/L	0-40	01
ALT (SGPT)	40	High	IU/L	0-32	01
Creatinine, Urine	175.0		mg/dL	Not Estab.	01
Albumin, Urine	50.0		ug/mL	Not Estab.	01
Alb/Creat Ratio	29		mg/g creat	0-29	
			Normal:	0 - 29	
			Moderately increased:	30 - 300	
			Severely increased:	>300	

Patient Report



Patient: **SAMPLE REPORT, 140303**
 DOB: 01/10/2000

Patient ID:

Control ID:

Specimen ID: 068-996-9613-0
 Date collected: 03/09/2022 0000 Local

TESTS	RESULT	FLAG	UNITS	REFERENCE	INTERVAL	LAB
-------	--------	------	-------	-----------	----------	-----

Litholink CKD Program

Interpretation Note 02

Medical Director's Note: Effective 2/28/2022, Labcorp uses the 2021 CKD-EPI creatinine equation without a race factor to calculate and report eGFR results. eGFR results reported prior to this date using the 2009 CKD-EPI equation are no longer included in this report interpretation.

CHRONIC KIDNEY DISEASE:

EGFR, BLOOD PRESSURE, AND PROTEINURIA ASSESSMENT

Estimated GFR is 60 mL/min/1.73mE2 or above; this patient is not presently in CKD stage 3 or higher, therefore we are unable to provide suggestions for treatment or follow-up.

DISCLAIMER

These assessments and treatment suggestions are provided as a convenience in support of the physician-patient relationship and are not intended to replace the physician's clinical judgment. They are derived from national guidelines in addition to other evidence and expert opinion. The clinician should consider this information within the context of clinical opinion and the individual patient. SEE GUIDANCE FOR CHRONIC KIDNEY DISEASE PROGRAM: Kidney Disease Improving Global Outcomes (KDIGO) clinical practice guidelines are at <http://kdigo.org/home/guidelines/>. National Kidney Foundation Kidney Disease Outcomes Quality Initiative (KDOQI (TM)), with its limitations and disclaimers, are at www.kidney.org/professionals/KDOQI. This program is intended for patients who have been diagnosed with stages 3, 4, or pre-dialysis 5 CKD. It is not intended for children, pregnant patients, or transplant patients.

PDF . 02

01	RN	Labcorp Raritan 69 First Avenue, Raritan, NJ 08869-1800	Dir: Araceli B Reyes, MD
02	LITIL	Litholink Corporation 150 Spring Lake Dr Ste A, Itasca, IL 60143-2091	Dir: John Asplin, MD

For inquiries, the physician may contact **Branch: 800-222-7566 Lab: 800-631-5250**

Accessions: 06899696130

DISCLAIMER: These assessments and treatment suggestions are provided as a convenience in support of the physician-patient relationship and are not intended to replace the physician's clinical judgment. They are derived from national guidelines in addition to other evidence and expert opinion. The clinician should consider this information within the context of clinical opinion and the individual patient.

SEE GUIDANCE FOR CHRONIC KIDNEY DISEASE PROGRAM: Kidney Disease Improving Global Outcomes (KDIGO) clinical practice guidelines are at <http://kdigo.org/home/guidelines/>. National Kidney Foundation Kidney Disease Outcomes Quality Initiative (KDOQI (TM)), with its limitations and disclaimers, are at www.kidney.org/professionals/KDOQI. This program is intended for patients who have been diagnosed with stages 3, 4, or pre-dialysis 5 CKD. It is not intended for children, pregnant patients, or transplant patients.

Note: Please refer to your LabCorp Report for all results as well as any test-specific and specimen-specific comments.

Laboratory Director's Notes

Laboratory test values flagged with an asterisk (*) within this report refer to the following commentary from our physicians and quality assurance staff.

COLLECTION DATE	ITEM	RELATED NOTES
03/09/2022		Effective 2/28/2022, Labcorp uses the 2021 CKD-EPI creatinine equation without a race factor to calculate and report eGFR results. eGFR results reported prior to this date using the 2009 CKD-EPI equation are no longer included in this report interpretation.

John Asplin, MD - Laboratory Director

Chronic Kidney Disease

Analysis & Treatment Suggestions

GENDER	DIABETES	CURRENT eGFR	MOST RECENT CKD STAGE
F	?	62	

Prognosis of CKD by GFR And Albuminuria Categories

GFR Categories: (ml/min/1.73m ²)		A1	A2	A3
G1	>=90 NORMAL OR HIGH	●		
G2	60-89 MILDLY DECREASED	●		
G3a	45-59 MILDLY TO MODERATELY DECREASED			
G3b	30-44 MODERATELY TO SEVERELY DECREASED			
G4	15-29 SEVERELY DECREASED			
G5	<15 KIDNEY FAILURE			

Persistent Albuminuria Categories

A1 = NORMAL TO MILDLY INCREASED; ACR <30 ug/mg; PCR <=200 mg/g

A2 = MODERATELY INCREASED; ACR 30-300 ug/mg; PCR 201-500 mg/g

A3 = SEVERELY INCREASED; ACR >300 ug/mg; PCR >500 mg/g

● = LOW RISK

● = MODERATELY INCREASED RISK

■ = HIGH RISK

■ = VERY HIGH RISK

● = PATIENT'S RESULT

Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. *Kidney inter.; Suppl.* 2013; 3: 1-150.

eGFR, Blood Pressure, and Proteinuria

Estimated GFR is 60 mL/min/1.73m² or above; this patient is not presently in CKD stage 3 or higher, therefore we are unable to provide suggestions for treatment or follow-up.

Your Test Results



WITHIN GOAL



BORDERLINE



OUT OF GOAL

Test	Your Results	Comments
------	--------------	----------



Kidney Health

eGFR estimates how well your kidneys are filtering blood. The higher the number, the better your kidneys are working.

62

Ref Range: >59
mL/min/1.73mE2

YOUR RESULT SHOWS MILDLY LOW KIDNEY FUNCTION. Control of diabetes and blood pressure can help to preserve kidney function.

URINE ALBUMIN : CREATININE RATIO is a test that looks for albumin in the urine, a sign of kidney damage. Higher amounts also put you at risk for heart disease and loss of kidney function. The lower the result, the better.



28.6

Ref. Range: 0 to 30 mg/g creat

YOUR URINE ALBUMIN IS NORMAL. Controlling conditions like high blood pressure and diabetes can help keep your urine albumin in the normal range. Regular exercise, weight loss, and quitting smoking are also beneficial for both heart and kidney health.

DISCLAIMER: You should discuss this information with your physician. Labcorp does not have a doctor-patient relationship with you, nor does it have access to a complete medical history or physical examination conducted by a physician that would be necessary for a complete diagnosis and comprehensive treatment plan. Neither you nor your physician should rely solely on this guidance. Bolded result descriptions in "Comments" consider either the reference range or target range for the test result. Reference range refers to the Labcorp reference interval. Target range refers to the guideline-suggested goal. REFERENCES: National Kidney Foundation Kidney Disease Outcomes Quality Initiative (KDOQI) at www.Kidney.org and Kidney Disease Improving Global Outcomes (KDIGO) at <http://kdigo.org>. Adapted from: https://www.niddk.nih.gov/-/media/Files/Health-Information/Health-Professionals/Kidney-Disease/Your_Kidney_Test_Results_EN.pdf.

